Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule and antibody agents that target the immune system to treat patients with cancer. Its programs aim to block or modify crucial immune checkpoints and reprogram T cells. The company has an oral small molecule checkpoint inhibitor advancing toward clinic, with a Phase 1B trial scheduled to begin in the first quarter of 2016 and an expansion cohort to test the inhibitor alone and in combination with another checkpoint inhibitor in several cancer types. Corvus plans to use proceeds from the financing to expand its research and development programs across multiple immuno-oncology assets and to initiate a multicenter Phase 1B trial. The company completed a $75 million Series B financing. It is based in Burlingame, California.

Total raised

$75M

Funding rounds

1

Latest round

Series B

Latest activity

Sep 2015